midazolam has been researched along with Libman-Sacks Disease in 1 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cestari, RN | 1 |
| de Oliveira, RDR | 1 |
| de Souza, FFL | 1 |
| Pippa, LF | 1 |
| Nardotto, GHB | 1 |
| Rocha, A | 1 |
| Donadi, EA | 1 |
| Lanchote, VL | 1 |
1 trial available for midazolam and Libman-Sacks Disease
| Article | Year |
|---|---|
Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin.
Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Case-Control Studies; Chemokine CCL2; Cytochrome | 2020 |